We eat a lot, wrongly, move a little. And we've been doing it for years. We lose weight, and we often do not think this is a problem. This is, however, for ours liver, which eventually becomes "fat" and leads to the risk of inflammation and develops into liver cirrhosis.
About 25 percent of the general population, one of the four Italians, suffers from fatty liver (or steatosis, it's a medical term), as it did at a recent conference in Rome promoted by Gilead Sciences. "It's an average value, we need to keep in mind that as many people overweight, obese or become diabetic, it's a greater risk of increasing stomatosis, up to 50 percent" warns Salvatore Petta, a gastroenterologist at Palermo and a secretary of the Italian Liver Research Association. "And this is an asymptomatic condition, often the diagnosis happens accidentally: abdominal ultrasound is for other reasons, and when looking at the liver it looks great because full fat", Continue Petta: "Today, there are advanced tests that combine blood tests, including liver enzymes such as transaminases, with a body mass index.This information, thanks to artificial intelligence, allows us to identify the most dangerous liver injuries".
Can I get back from steatosis? Several scientific studies have shown convincingly that losing at least 7% of their weight (with lower calorie diet and a more regular lifestyle) improves liver conditions: inflammation is regressed as well as liver fibrosis. Meanwhile, scientific research continues to develop therapies that can provide a solution to the most serious problem, such as steatosis. "For some time we have focused on determining the treatment of those affected by alcoholic steatohepatitis at the most advanced stages. – says Valentino Confalone, General Director of Science of the Gilead -. We have more molecules in the studio. Some are in Phase III trials against advanced fibrosis and cirrhosis, while others are at Phase II. We also work on non-invasive diagnostic methods that are as effective as biopsy and are based on the techniques of learning the artificial intelligence machine ".
As for liver disease, steatosis is still an open challenge. He is on the same front to win another challenge, hepatitis C. "Liver health is a priority for us – adds Confalone – we are proud that we have been pioneers in available therapeutic regimens that provide total recovery and are an active part of the scientific societies, institutions and associations of patients that by 2030 they are going to remove hepatitis C from our country, the WHO. We also provided therapies for those fewer patients who did not respond to previous treatments and therefore deprived of an effective drug. Furthermore, together with AIFA and Italian pediatricians, we have made available at the nominal price the only treatment currently available for adolescents aged 12 to 18 who suffer from viruses. Now the next challenge we want to win is precisely that of steatosis ".
© Reproduction Reserved